戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ioural disturbances and were associated with frontotemporal atrophy and indirect measures of GABAergi
2  data determined the presence of significant frontotemporal atrophy to dichotomize the participants i
3 d map these to the patients' distribution of frontotemporal atrophy.
4 esis, the degree to which modularity of this frontotemporal auditory control network is increased rel
5 ntences in memory identify the phase of left frontotemporal beta oscillations as the most prominent i
6 l components of binding, across temporal and frontotemporal cortex, respectively.
7 ortex and theta phase synchronization across frontotemporal cortex.
8 uantify network dynamics and connectivity in frontotemporal cortex.
9         Reduced haemodynamic response in the frontotemporal cortices of patients with major depressiv
10 2 is the most prominent mutation in familial frontotemporal degeneration (FTD) and amyotrophic latera
11 s on amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD).
12 ated with neurodegenerative diseases such as frontotemporal degeneration and Alzheimer disease.
13 tudy and the validation cohort from the Penn Frontotemporal Degeneration Center (data collected betwe
14 iated with amyotrophic lateral sclerosis and frontotemporal degeneration(1).
15 gy, and in amyotrophic lateral sclerosis and frontotemporal degeneration.
16                 We assessed 31 patients with frontotemporal dementia (10 with behavioural variant, 11
17  behavioural impairment (ALSbi) and ALS with frontotemporal dementia (ALS-FTD)).
18 C model of amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD) that recapitulates DNA
19 ived from amyotrophic lateral sclerosis with frontotemporal dementia (ALS/FTD)-associated GGGGCC (G4C
20 iated with amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD).
21 es such as amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD).
22 ng C9orf72 Amyotrophic Lateral Sclerosis and Frontotemporal Dementia (ALS/FTD).
23  in amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (ALSFTD-1) have been modified (A
24 other neurodegenerative disorders, including frontotemporal dementia (AUC=82.76-100% across cohorts),
25 to-insular stroke (FIS), behavioural variant frontotemporal dementia (bvFTD) and Alzheimer's disease
26 l cohort of patients with behavioral variant frontotemporal dementia (bvFTD) and semantic variant pri
27 lzheimer disease (AD) and behavioral-variant frontotemporal dementia (bvFTD) are still limited.
28                   The behavioural variant of frontotemporal dementia (bvFTD) is a frequent cause of e
29 agnosis in patients with behavioural variant frontotemporal dementia (bvFTD) poses a daunting challen
30 ctural changes in the behavioural variant of frontotemporal dementia (bvFTD); and to correlate cortic
31 c cause of amyotrophic lateral sclerosis and frontotemporal dementia (C9ALS/FTD).
32 f familial amyotrophic lateral sclerosis and frontotemporal dementia (c9ALS/FTD).
33 n familial amyotrophic lateral sclerosis and frontotemporal dementia (collectively, C9ALS/FTD).
34 G(4)C(2)) repeat expansions in C9orf72 cause frontotemporal dementia (FTD) and amyotrophic lateral sc
35             The precise relationship between frontotemporal dementia (FTD) and amyotrophic lateral sc
36  of repeat expansions in the pathogenesis of frontotemporal dementia (FTD) and amyotrophic lateral sc
37 ause amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) and lead to the production
38      Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are associated with loss o
39      Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are neurodegenerative diso
40      Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are overlapping neurodegen
41      Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two related neurodegen
42 AD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) as well as in the wild-typ
43  is observed in >95% of ALS and tau-negative frontotemporal dementia (FTD) cases.
44 lial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) cases.
45                The clinical heterogeneity of frontotemporal dementia (FTD) complicates identification
46      Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) constitute aggressive neur
47                                              Frontotemporal dementia (FTD) is a common neurogenerativ
48 e of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is a hexanucleotide repeat
49                                              Frontotemporal dementia (FTD) is a pathologically hetero
50                                              Frontotemporal dementia (FTD) is an early onset dementia
51                                              Frontotemporal dementia (FTD) is characterized by neuron
52                                              Frontotemporal dementia (FTD) is the second most prevale
53                                              Frontotemporal dementia (FTD) is typically associated wi
54       QC-01-175 effected clearance of tau in frontotemporal dementia (FTD) patient-derived neuronal c
55                                Patients with frontotemporal dementia (FTD) resulting from granulin (G
56                                          The frontotemporal dementia (FTD) spectrum is a heterogeneou
57                                          The frontotemporal dementia (FTD) spectrum of neurodegenerat
58 with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) susceptibility, and may un
59 G PET studies of Alzheimer dementia (AD) and frontotemporal dementia (FTD) to derive a limit for redu
60 otein aggregation in seven cases of familial frontotemporal dementia (FTD) with mutations in MAPT, GR
61 s the pathogenesis of tauopathies, including frontotemporal dementia (FTD) with tau inclusions.
62 dy dementia (LBD), Parkinson's disease (PD), frontotemporal dementia (FTD), amyotrophic lateral scler
63 2 cause amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerati
64 In cross-sectional studies of presymptomatic frontotemporal dementia (FTD), higher education has been
65 s emerging as an early pathological event in frontotemporal dementia (FTD), however biomarkers are la
66   In amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), pathology is often associ
67 arious neurodegenerative diseases, including frontotemporal dementia (FTD), progressive supranuclear
68 ed with AD, P301L mutant tau associated with frontotemporal dementia (FTD), S320F mutant tau associat
69 ding amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), suggesting the hypothesis
70 s implicated in ALS have also been linked to frontotemporal dementia (FTD), suggesting these two dise
71 nts with amyotrophic lateral sclerosis (ALS)/Frontotemporal dementia (FTD), the (G4C2)-RNA repeat exp
72                                           In frontotemporal dementia (FTD), the high expressing TMEM1
73                             No treatment for frontotemporal dementia (FTD), the second most common ty
74 various neurodegenerative diseases including frontotemporal dementia (FTD), which can be caused by mu
75 e of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), yet a clear understanding
76                                              Frontotemporal dementia (FTD)-causing mutations in the C
77  The amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)-linked RNA-binding protein
78 uses amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
79 o early-onset Alzheimer's disease (EOAD) and frontotemporal dementia (FTD).
80 e of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
81 e of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
82 ause amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
83 f the brain in the neurodegenerative disease frontotemporal dementia (FTD).
84 r TMEM106B associate with risk of developing frontotemporal dementia (FTD).
85 xpansion is the most common genetic cause of frontotemporal dementia (FTD).
86 e of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
87  for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
88 ophic lateral sclerosis (ALS) and subsets of frontotemporal dementia (FTD).
89 e in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
90 e (AD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD).
91 ted tremor ataxia syndrome (FXTAS), ALS, and frontotemporal dementia (FTD).
92 cause of amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD).
93 nding protein implicated in familial ALS and frontotemporal dementia (FTD).
94  diseases, including Alzheimer's disease and frontotemporal dementia (FTD).
95 ses in in vivo and in vitro models of AD and frontotemporal dementia (FTD).
96 both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
97  There are few validated fluid biomarkers in frontotemporal dementia (FTD).
98 e of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
99 e of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
100 al ALS (fALS), sporadic ALS (sALS), ALS with frontotemporal dementia (FTD-ALS), and Alzheimer's disea
101  associated with Paget's disease of bone and frontotemporal dementia (IBM-PFD)-together with its adap
102 dy myopathy with Paget's disease of bone and frontotemporal dementia (IBMPFD) that harbor germline mu
103 impairment (MNDcbi)) or motor neuron disease-frontotemporal dementia (MND-FTD).
104 ior disorder (n = 1), and behavioral-variant frontotemporal dementia (n = 1).
105 oral dementia syndromes: behavioural variant frontotemporal dementia (n = 77) and the semantic (n = 4
106 The concept of the right temporal variant of frontotemporal dementia (rtvFTD) is still equivocal.
107 rodegenerative disorders: behavioral variant frontotemporal dementia [(bvFTD); n = 35] and Alzheimer'
108 tients with TDP-43 proteinopathies (ALS, ALS-frontotemporal dementia [ALS-FTD], and FTLD-TDP-43 [FTLD
109  Seventeen patients with behavioural variant frontotemporal dementia [four female; mean (standard dev
110 fects, respectively, in clinical subtypes of frontotemporal dementia against neurologically normal co
111 h FTLD (15 patients with behavioural variant frontotemporal dementia and 18 with progressive supranuc
112 non-FTLD donors with a clinical diagnosis of frontotemporal dementia and a different pathological sub
113  in the central nervous system characterizes frontotemporal dementia and ALS in many individuals with
114  in many neurodegenerative diseases, such as frontotemporal dementia and Alzheimer's disease.
115                                              Frontotemporal dementia and amyotrophic lateral sclerosi
116 n C9orf72, which is the most common cause of frontotemporal dementia and amyotrophic lateral sclerosi
117 amily with autosomal dominant inheritance of frontotemporal dementia and amyotrophic lateral sclerosi
118                         Mutations in several frontotemporal dementia and amyotrophic lateral sclerosi
119  autophagy regulation in the pathogenesis of frontotemporal dementia and amyotrophic lateral sclerosi
120 s tauopathies-including Alzheimer's disease, frontotemporal dementia and chronic traumatic encephalop
121 oncept of progranulin-boosting therapies for frontotemporal dementia and highlight an important role
122 ese findings support an overlap between MND, frontotemporal dementia and neuropsychiatric disorders,
123 erebral blood flow shows differences between frontotemporal dementia and other forms of dementia, the
124 72-related amyotrophic lateral sclerosis and frontotemporal dementia and other neurodegenerative dise
125 ule-associated protein tau), which can cause frontotemporal dementia and parkinsonism linked to chrom
126 al targets for symptomatic drug treatment of frontotemporal dementia and progressive supranuclear pal
127                            Participants with frontotemporal dementia and progressive supranuclear pal
128 s a disease progression biomarker in genetic frontotemporal dementia and suggest that longitudinal Nf
129  selection of trial endpoints for studies in frontotemporal dementia and support the use of neuroimag
130 inclusions are found in 10% of patients with frontotemporal dementia and those with amyotrophic later
131 ith at least three other proteins encoded by frontotemporal dementia and/or amyotrophic lateral scler
132                    The clinical syndromes of frontotemporal dementia are clinically and neuropatholog
133                             Genetic forms of frontotemporal dementia are most commonly due to mutatio
134 gene cause amyotrophic lateral sclerosis and frontotemporal dementia characterized by dipeptide-repea
135  progressive aphasia and behavioural variant frontotemporal dementia differed from controls in the ex
136 centre cohort study of families with genetic frontotemporal dementia done across Europe and Canada.
137 le participants (aged >=18 years) either had frontotemporal dementia due to a pathogenic mutation in
138  deficits in Grn+/- mice, an animal model of frontotemporal dementia due to GRN mutations.
139                      Most imaging studies in frontotemporal dementia have been cross-sectional, and f
140 familial amyotrophic lateral sclerosis (ALS)/frontotemporal dementia in humans through an unknown mec
141                   In the multicentre GENetic Frontotemporal dementia Initiative (GENFI) study, we inv
142 hy non-carriers participating in the Genetic Frontotemporal dementia Initiative (GENFI), all of whom
143 from 14 centres collaborating in the Genetic Frontotemporal Dementia Initiative (GENFI), which is a m
144 The current study used data from the Genetic Frontotemporal Dementia Initiative multicentre cohort st
145          Data were obtained from the Genetic Frontotemporal Dementia Initiative.
146                                              Frontotemporal dementia is a heterogenous neurodegenerat
147 om onset and at death of people with genetic frontotemporal dementia is influenced by genetic group a
148 ired for transport (ESCRT) machinery, causes frontotemporal dementia linked to chromosome 3 (FTD3).
149                                 In tauopathy-frontotemporal dementia mice, both drugs were neuroprote
150 it was hypothesized that behavioural variant frontotemporal dementia might also be associated with al
151  PPA while patients with behavioural variant frontotemporal dementia often had semantic impairments.
152 Of 619 subjects with a clinical diagnosis of frontotemporal dementia or primary progressive aphasia,
153                   By contrast, expression of frontotemporal dementia P301L mutant Tau immobilizes Fyn
154 line derived from a C9orf72-HRE positive ALS/frontotemporal dementia patient using CRISPR/Cas9 genome
155 l expansions in the C9orf72 gene through the Frontotemporal Dementia Prevention Initiative and from p
156                                              Frontotemporal dementia refers to a group of progressive
157 hometry of patients with behavioural variant frontotemporal dementia revealed that the inability to s
158 als, the routine evaluation of patients with frontotemporal dementia should include the presence and
159           Genome-wide association studies in frontotemporal dementia showed limited success in identi
160 d their expected age of symptom onset in key frontotemporal dementia signature regions.
161 oinflammation were associated with different frontotemporal dementia syndromes and supported accurate
162  a cohort of patients representing all major frontotemporal dementia syndromes relative to healthy ag
163 ng of emotional signals is a core feature of frontotemporal dementia syndromes, but the underlying ne
164 gitudinal changes in 161 patients with three frontotemporal dementia syndromes: behavioural variant f
165 od flow signature of presymptomatic, genetic frontotemporal dementia using a voxel-based approach.
166 europsychiatric International Consortium for Frontotemporal Dementia was recently established to dete
167  stimulus, patients with behavioural variant frontotemporal dementia were less motivated, and therefo
168 allmark of amyotrophic lateral sclerosis and frontotemporal dementia where cytoplasmic TDP-43 inclusi
169 llular accumulation of tau mutants linked to frontotemporal dementia with parkinsonism and alpha-synu
170 gnostic biomarker in presymptomatic familial frontotemporal dementia', by Jiskoot et al. (doi:10.1093
171 ributes to amyotrophic lateral sclerosis and frontotemporal dementia(1,2).
172 , are found in patients with Pick's disease (frontotemporal dementia).
173 th other neurodegenerative diseases (20 with frontotemporal dementia, 20 with Alzheimer's disease, 19
174 tions in VCP cause Paget disease of bone and frontotemporal dementia, an autosomal dominant multisyst
175  of APOE and TOMM40 with behavioural variant frontotemporal dementia, and ARHGAP35 and SERPINA1 with
176 in neurons in amyotrophic lateral sclerosis, frontotemporal dementia, and other neurodegenerative dis
177 set of neurodegenerative diseases, including frontotemporal dementia, certain repeat expansion diseas
178  neurodegenerative disorders, including ALS, frontotemporal dementia, chronic traumatic encephalopath
179 odegenerative diseases (Alzheimer's disease, frontotemporal dementia, corticobasal syndrome, and prog
180 rosis and altered motor cortical function in frontotemporal dementia, demonstration of cholinergic de
181 cal manifestation of Alzheimer's disease and frontotemporal dementia, diseases characterized by the a
182 allmark of amyotrophic lateral sclerosis and frontotemporal dementia, how aggregates form and what dr
183 s)-Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Huntington's disease, and amyot
184 evalence of amyotrophic lateral sclerosis or frontotemporal dementia, indicating that either genetic
185 ) and the related neurodegenerative disorder frontotemporal dementia, is the cellular mislocalization
186  degeneration, including behavioural variant frontotemporal dementia, non-fluent, and semantic varian
187 n sera of patients with Alzheimer's Disease, frontotemporal dementia, or Parkinson's Disease.
188  developing amyotrophic lateral sclerosis or frontotemporal dementia, or to slow progression.
189 ively unimpaired, mild cognitive impairment, frontotemporal dementia, probable dementia with Lewy bod
190 t spans behavioural and language variants of frontotemporal dementia, progressive supranuclear palsy
191 a with Lewy bodies, multiple system atrophy, frontotemporal dementia, progressive supranuclear palsy,
192 u linked to familial Parkinson's disease and frontotemporal dementia, respectively, reduced neurite o
193                             The pathology of frontotemporal dementia, termed frontotemporal lobar deg
194  diseases, including Alzheimer's disease and frontotemporal dementia, the hyperphosphorylation of tau
195 e of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, though the mechanisms by which
196 L) is a promising blood biomarker in genetic frontotemporal dementia, with elevated concentrations in
197 inning complex socio-emotional phenotypes of frontotemporal dementia, with implications for novel phy
198 ge cohort of presymptomatic subjects bearing frontotemporal dementia-related pathogenic mutations.
199 e impairment (MCI), Alzheimer's disease, and frontotemporal dementia.
200 e diseases amyotrophic lateral sclerosis and frontotemporal dementia.
201 tauopathies, such as Alzheimer's disease and frontotemporal dementia.
202 roach to elucidate the disease mechanisms in frontotemporal dementia.
203 e of its utility in presymptomatic stages of frontotemporal dementia.
204 h as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
205 n cause of amyotrophic lateral sclerosis and frontotemporal dementia.
206  including amyotrophic lateral sclerosis and frontotemporal dementia.
207 ker for the presymptomatic stages of genetic frontotemporal dementia.
208 L over time in the various stages of genetic frontotemporal dementia.
209  patients with amyotrophic lateral sclerosis/frontotemporal dementia.
210 ders amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
211  with presymptomatic and symptomatic genetic frontotemporal dementia.
212 s of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
213 c cause of amyotrophic lateral sclerosis and frontotemporal dementia.
214 neuroinflammation and protein aggregation in frontotemporal dementia.
215 enic mouse model akin to genetic variants of frontotemporal dementia.
216 atterns of the diverse clinical syndromes of frontotemporal dementia.
217                 Parkinson's disease (PD) and frontotemporal dementia/amyotrophic lateral sclerosis (F
218 's disease and amyotrophic lateral sclerosis/frontotemporal dementia/myopathy, respectively.
219  particularly amyotrophic lateral sclerosis, frontotemporal dementias and Alzheimer disease.
220 ogenesis in Alzheimer's disease, a subset of frontotemporal dementias, and other tauopathies.
221  inclusions that define Alzheimer's disease, frontotemporal dementias, and other tauopathies.
222 bule-associated protein tau (MAPT) can cause frontotemporal dementias.
223                                              Frontotemporal dysconnectivity is a key pathology in sch
224 nd changes in white matter microstructure in frontotemporal fiber tracts.
225        Genotype effects were not observed in frontotemporal GM volume.
226  vision, the "VWFA" is incorporated into the frontotemporal language network and participates in high
227 ening, conditions that strongly activate the frontotemporal language network.
228 nd (2) the VWFA connected more strongly with frontotemporal language regions than with regions adjace
229                                We describe a frontotemporal learning network, which exploits relation
230 er the curve of 0.894) and autopsy-confirmed frontotemporal lobar degeneration (area under the curve
231 any neurodegenerative pathologies, including frontotemporal lobar degeneration (FTLD) and amyotrophic
232 gical syndromes: haploinsufficiency leads to frontotemporal lobar degeneration (FTLD) and nullizygosi
233 ospinal fluid (CSF) has been associated with frontotemporal lobar degeneration (FTLD) in clinical ser
234  (AD) pathology (n=21) and those with likely frontotemporal lobar degeneration (FTLD) pathology (n=45
235 isease (AD), although sensitive detection of frontotemporal lobar degeneration (FTLD) tau inclusions
236 linical diagnosis of PPA was associated with frontotemporal lobar degeneration (FTLD) with transactiv
237 er's disease (AD), Parkinson's disease (PD), frontotemporal lobar degeneration (FTLD), and amyotrophi
238 pathology of frontotemporal dementia, termed frontotemporal lobar degeneration (FTLD), is characteriz
239                   Unlike many other forms of frontotemporal lobar degeneration (FTLD), svPPA has a hi
240 llele causes haploinsufficiency and leads to frontotemporal lobar degeneration (FTLD), the second lea
241 mon feature of the syndromes associated with frontotemporal lobar degeneration (FTLD).
242 g within the clinicopathological spectrum of frontotemporal lobar degeneration (FTLD).
243 with amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).
244 common neurodegenerative disorders including frontotemporal lobar degeneration (FTLD).
245 nd in approximately 50% of patients dying of frontotemporal lobar degeneration (FTLD).
246 icantly increased in brains of patients with frontotemporal lobar degeneration (FTLD-tau), a disease
247 nd a substantial proportion of patients with frontotemporal lobar degeneration (~45%) exhibit TDP-43
248  disease = 1, vascular brain injury = 1, and frontotemporal lobar degeneration = 2).
249 f-function mutations in the PGRN gene causes frontotemporal lobar degeneration accompanied by TDP-43
250 ration, 50 with Alzheimer's disease, 19 with frontotemporal lobar degeneration and 54 healthy individ
251 ATE shares pathogenetic mechanisms with both frontotemporal lobar degeneration and Alzheimer's diseas
252 cribed as a significant risk factor for both frontotemporal lobar degeneration and Alzheimer's diseas
253          The PREV-DEMALS (Predict to Prevent Frontotemporal Lobar Degeneration and Amyotrophic Latera
254 th risk of neurodegenerative diseases beyond frontotemporal lobar degeneration are enriched in CTCF-b
255            Amyotrophic lateral sclerosis and frontotemporal lobar degeneration are incurable motor ne
256 g protein TDP-43 in neurons is a hallmark of frontotemporal lobar degeneration caused by haploinsuffi
257                                 The modified frontotemporal lobar degeneration clinical dementia rati
258 ean diffusivity correlated with the modified frontotemporal lobar degeneration clinical dementia rati
259 ormed correlation analyses with the modified frontotemporal lobar degeneration clinical dementia rati
260  results show that syndromes associated with frontotemporal lobar degeneration do not form discrete m
261                      The syndromes caused by frontotemporal lobar degeneration have highly heterogene
262 tients (98 amnestic; 20 non-amnestic) and 64 frontotemporal lobar degeneration patients (five amnesti
263 s with non-Alzheimer tauopathies and non-tau frontotemporal lobar degeneration showed a range of trac
264  transdiagnostic approach to the spectrum of frontotemporal lobar degeneration syndromes provides a u
265 egeneration, argyrophilic grain disease, and frontotemporal lobar degeneration with MAPT mutations),
266  tau astrogliopathy and multiple subtypes of frontotemporal lobar degeneration with tau inclusions.
267 assification issues among LATE-NC, ADNC, and frontotemporal lobar degeneration with TDP-43 (FTLD-TDP)
268                   LATE is distinguished from frontotemporal lobar degeneration with TDP-43 pathology
269 ases, such as amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's disea
270 tissue samples from pathologically confirmed frontotemporal lobar degeneration, and in silico techniq
271  ATN framework was relatively insensitive to frontotemporal lobar degeneration, and these patients we
272 nating non-amnestic Alzheimer's disease from frontotemporal lobar degeneration, compared to discrimin
273 ients with a syndrome likely to be caused by frontotemporal lobar degeneration, including behavioural
274 nalysis of the 7p21 locus linked by GWASs to frontotemporal lobar degeneration, nominating a causal v
275 PGRN) underlie the neurodegenerative disease frontotemporal lobar degeneration, while homozygous loss
276 ng the Mini-Mental State Examination (MMSE), Frontotemporal Lobar Degeneration-Clinical Dementia Rati
277  grey matter regions, but not with change in Frontotemporal Lobar Degeneration-Clinical Dementia Rati
278 effective in discriminating both groups from frontotemporal lobar degeneration.
279 ase and some forms of non-amyloid-associated frontotemporal lobar degeneration.
280 as initially identified as a risk factor for frontotemporal lobar degeneration.
281  with MAPT mutations), and three had non-tau frontotemporal lobar degeneration.
282 ically diagnosed or autopsy-confirmed AD and frontotemporal lobar degeneration.
283 ination of amnestic Alzheimer's disease from frontotemporal lobar degeneration.
284              In conditions distinct from the frontotemporal lobar degenerations, TDP-43 appears to pr
285 like amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD).
286 s of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Dementia (FTLD).
287 milarity analyses revealed that the phase of frontotemporal low-frequency oscillations, primarily in
288 at the high-frequency activity recorded over frontotemporal MEG sensors plays a critical role in choi
289  the auditory cortex and bilateral STG and a frontotemporal network involving connections of the left
290 from the language-selective left-lateralized frontotemporal network, language comprehension sometimes
291 ncephalography with dynamic causal models of frontotemporal networks provides a potential platform on
292 m induces robust perturbations that permeate frontotemporal networks, including an evoked 'mismatch n
293 viour and face recognition into a continuous frontotemporal neurocognitive space.
294 lvian fissure, we compared the growth of the frontotemporal opercula over the insular cortex and comp
295 ar volume and cerebral cortical thickness in frontotemporal regions (i.e., overlapping with areas tha
296 found increased cortical mean diffusivity in frontotemporal regions, but only minimal loss of cortica
297 g between each patient group and controls in frontotemporal regions, in both a regions-of-interest an
298 ased [(11)C]PK11195 binding predominantly in frontotemporal regions, with additional regions showing
299 ships of information flow within and between frontotemporal regions.
300 activity (175-250 Hz) distributed over right frontotemporal sensors correlated with delay and reward

 
Page Top